Naoxintong Retards Atherosclerosis by Inhibiting Foam Cell Formation through Activating PPARα Pathway

BACKGROUNDS: We recently reported that Naoxintong (NXT), a China Food and Drug Administration (FDA)-approved cardiac medicine, could reduce the plaque size, but the underlying mechanism remains elusive now. OBJECTIVE: In this study, we investigated the effects of NXT on foam cell accumulation both i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Curr Mol Med
Egile Nagusiak: Wang, Zeng, Shi, Huairui, Zhao, Huan, Dong, Zhen, Zhao, Buchang, Weng, Xinyu, Liu, Rongle, Hu, Kai, Zou, Yunzeng, Sun, Aijun, Ge, Junbo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Bentham Science Publishers 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6463403/
https://ncbi.nlm.nih.gov/pubmed/30734676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1566524019666190207143207
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak